乳酸菌联合三联疗法治疗幽门螺杆菌相关复发性口腔溃疡的疗效分析

Effecacy of lactobacillus combined with triple therapy on Helicobacter pylori-related recurrent oral ulcer

摘要:

目的观察乳酸菌联合三联疗法治疗幽门螺杆菌相关复发性口腔溃疡的临床疗效。 方法将90例幽门螺杆菌相关复发性口腔溃疡患者均分为三联疗法组及乳酸菌联合组,三联疗法组采取克拉霉素缓释片、阿莫西林胶囊、胶体果胶铋胶囊治疗,乳酸菌联合组在三联疗法组的基础上联合乳酸菌胶囊治疗,两组连续治疗7天。观察两组临床有效率、创面愈合时间、幽门螺杆菌根除率、疾病复发率及不良反应发生率。视觉模拟评分(VAS)评估疼痛程度,ELISA法测定血清肿瘤坏死因子-α(TNF-α)、白细胞介素-1(IL-1)、IL-6水平。结果治疗后,乳酸菌联合组患者VAS评分、创面愈合时间、疾病复发率、不良反应发生率低于三联疗法组(P＜0.05),临床有效率、幽门螺杆菌根除率高于三联疗法组(P＜0.05)。乳酸菌联合组血清TNF-α、IL-1、IL-6水平均低于三联疗法组(P＜0.05)。 结论乳酸菌联合三联疗法治疗幽门螺杆菌相关复发性口腔溃疡能提高其疗效,缓解疼痛程度,降低血清炎症因子水平。

Abstract:

To investigate the clinical effect of lactobacillus combined with triple therapy on Helicobacter pylori-related recurrent oral ulcer. MethodsNinety cases of Helicobacter pylori-related recurrent oral ulcer patients were divided into triple therapy group and lactobacillus combined group. The triple therapy group was treated with clarithromycin sustained release tablets, amoxicillin capsules and colloidal bismuth pectin capsules, and the lactobacillus combined group was treated with lactobacillus capsules on the basis of the triple therapy group. The two groups were treated for 7 consecutive days. The clinical effective rate, wound healing time, Helicobacter pylori eradication rate, disease recurrence rate and adverse reaction rate were observed. Visual analog scale (VAS) was used to assess the degree of pain,the serum levels of tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6 were measured by ELISA. ResultsAfter treatment, the VAS score, wound healing time, disease recurrence rate and incidence of adverse reactions in lactobacillus combined group were lower than those in triple therapy group(P＜0.05). The clinical effective rate and eradication rate of Helicobacter pylori were higher than those of triple therapy group(P＜0.05). The serum levels of TNF-α, IL-1 and IL-6 in lactobacillus combined group were lower than those in triple therapy group(P＜0.05). ConclusionLactobacillus combined with triple therapy in the treatment of Helicobacter pylori-related recurrent oral ulcer can improve its efficacy, relieve pain, and reduce the level of serum inflammatory factors.